These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 20435600

  • 1. The different effects of early and late bevacizumab (Avastin) injection on inhibiting corneal neovascularization and conjunctivalization in rabbit limbal insufficiency.
    Lin CT, Hu FR, Kuo KT, Chen YM, Chu HS, Lin YH, Chen WL.
    Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6277-85. PubMed ID: 20435600
    [Abstract] [Full Text] [Related]

  • 2. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
    Chen WL, Lin CT, Lin NT, Tu IH, Li JW, Chow LP, Liu KR, Hu FR.
    Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
    Kim TI, Kim SW, Kim S, Kim T, Kim EK.
    Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.
    Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA.
    Am J Ophthalmol; 2008 Mar; 145(3):424-431. PubMed ID: 18207123
    [Abstract] [Full Text] [Related]

  • 5. Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition.
    Chu HS, Hu FR, Yang CM, Yeh PT, Chen YM, Hou YC, Chen WL.
    Cornea; 2011 Jan; 30(1):60-6. PubMed ID: 20847676
    [Abstract] [Full Text] [Related]

  • 6. Anti-VEGF therapy (bevacizumab) for sulfur mustard-induced corneal neovascularization associated with delayed limbal stem cell deficiency in rabbits.
    Kadar T, Amir A, Cohen L, Cohen M, Sahar R, Gutman H, Horwitz V, Dachir S.
    Curr Eye Res; 2014 May; 39(5):439-50. PubMed ID: 24215293
    [Abstract] [Full Text] [Related]

  • 7. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
    Avisar I, Weinberger D, Kremer I.
    Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
    [Abstract] [Full Text] [Related]

  • 8. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
    Hashemian MN, Moghimi S, Kiumehr S, Riazi M, Amoli FA.
    Ophthalmic Res; 2009 Feb; 42(2):90-5. PubMed ID: 19546599
    [Abstract] [Full Text] [Related]

  • 9. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.
    Hurmeric V, Mumcuoglu T, Erdurman C, Kurt B, Dagli O, Durukan AH.
    Cornea; 2008 Apr; 27(3):357-62. PubMed ID: 18362668
    [Abstract] [Full Text] [Related]

  • 10. Mechanisms controlling the effects of bevacizumab (avastin) on the inhibition of early but not late formed corneal neovascularization.
    Chen WL, Chen YM, Chu HS, Lin CT, Chow LP, Chen CT, Hu FR.
    PLoS One; 2014 Apr; 9(4):e94205. PubMed ID: 24714670
    [Abstract] [Full Text] [Related]

  • 11. Characterization of corneal pannus removed from patients with total limbal stem cell deficiency.
    Espana EM, Di Pascuale MA, He H, Kawakita T, Raju VK, Liu CY, Tseng SC.
    Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):2961-6. PubMed ID: 15326108
    [Abstract] [Full Text] [Related]

  • 12. Subconjunctival bevacizumab for corneal neovascularization.
    Zaki AA, Farid SF.
    Acta Ophthalmol; 2010 Dec; 88(8):868-71. PubMed ID: 19519730
    [Abstract] [Full Text] [Related]

  • 13. The effect of subconjunctival suramin on corneal neovascularization in rabbits.
    Lee HS, Chung SK.
    Cornea; 2010 Jan; 29(1):86-92. PubMed ID: 19907290
    [Abstract] [Full Text] [Related]

  • 14. Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization.
    Qian CX, Bahar I, Levinger E, Rootman D.
    Cornea; 2008 Oct; 27(9):1090-2. PubMed ID: 18812781
    [Abstract] [Full Text] [Related]

  • 15. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.
    Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O, Tura A, Grisanti S, Bartz-Schmidt KU, Szurman P, Tübingen Bevacizumab Study Group.
    Acta Ophthalmol; 2008 May; 86(3):322-8. PubMed ID: 17995975
    [Abstract] [Full Text] [Related]

  • 16. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.
    Hashemian MN, Z-Mehrjardi H, Moghimi S, Tahvildari M, Mojazi-Amiri H.
    Ophthalmic Res; 2011 May; 46(1):50-4. PubMed ID: 21212709
    [Abstract] [Full Text] [Related]

  • 17. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy.
    Oh JY, Kim MK, Wee WR.
    Cornea; 2009 Oct; 28(9):1070-3. PubMed ID: 19724199
    [Abstract] [Full Text] [Related]

  • 18. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.
    Öner V, Küçükerdönmez C, Akova YA, Çolak A, Karalezli A.
    Ophthalmic Res; 2012 Oct; 48(3):118-23. PubMed ID: 22538642
    [Abstract] [Full Text] [Related]

  • 19. Subconjunctival bevacizumab for corneal neovascularization.
    Doctor PP, Bhat PV, Foster CS.
    Cornea; 2008 Oct; 27(9):992-5. PubMed ID: 18812760
    [Abstract] [Full Text] [Related]

  • 20. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization.
    Habot-Wilner Z, Barequet IS, Ivanir Y, Moisseiev J, Rosner M.
    Acta Ophthalmol; 2010 Dec; 88(8):862-7. PubMed ID: 19549103
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.